The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg?

Critical Reviews in Oncology/Hematology

Volumn 86, Issue 3, 2013, Pages 278-289

  Russo, A ^a   Bronte, G ^a   Cabibi, D ^b   Bazan, V ^a   Cicero, G ^a   Bertani, A ^c   Rizzo, S ^a   Fiorentino, E ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

Author keywords

Adenocarcinoma; Barrett's esophagus; Dysplasia; Endoscopic surveillance; Metaplasia; MiRNAs

Indexed keywords

CYCLIN A; CYCLIN D; MICRORNA; PROTEIN P53; TRANSCRIPTION FACTOR CDX1; TRANSCRIPTION FACTOR CDX2;

BARRETT ESOPHAGUS; CANCER GROWTH; CARCINOGENESIS; CAUSAL ATTRIBUTION; DNA CONTENT; DYSPLASIA; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOGENESIS; GASTRIC METAPLASIA; GENE EXPRESSION; HUMAN; INTESTINE METAPLASIA; METAPLASIA; MOLECULAR PATHOLOGY; PATIENT MONITORING; REVIEW; TRANSCRIPTION FACTOR CDX1 GENE; TRANSCRIPTION FACTOR CDX2 GENE;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BIOLOGICAL MARKERS; CARCINOGENESIS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; HUMANS; MICRORNAS;

EID: 84877797367     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.12.001     Document Type: Review

References (91)

1. Jenkins G.J., Doak S.H., Parry J.M., D'Souza F.R., Griffiths A.P., Baxter J.N. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. The British Journal of Surgery 2002, 89:824-837.
2. Shaheen N.J., Richter J.E. Barrett's oesophagus. Lancet 2009, 373:850-861.
3. Gillen P., Keeling P., Byrne P.J., Healy M., O'Moore R.R., Hennessy T.P. Implication of duodenogastric reflux in the pathogenesis of Barrett's oesophagus. The British Journal of Surgery 1988, 75:540-543.
4. Souza R.F., Krishnan K., Spechler S.J. Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. American Journal of Physiology 2008, 295:G211-G218.
5. Playford R.J. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut 2006, 55:442.
6. Ronkainen J., Aro P., Storskrubb T., et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005, 129:1825-1831.
7. Dent J., El-Serag H.B., Wallander M.A., Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005, 54:710-717.
8. Garud S.S., Keilin S., Cai Q., Willingham F.F. Diagnosis and management of Barrett's esophagus for the endoscopist. Therapeutic Advances in Gastroenterology 2010, 3:227-238.
9. Spechler S.J., Clinical practice. Barrett's esophagus. The New England Journal of Medicine 2002, 346:836-842.
10. Devesa S.S., Blot W.J., Fraumeni J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998, 83:2049-2053.
11. Parker S.L., Tong T., Bolden S., Wingo P.A. Cancer statistics, 1997. CA: A Cancer Journal for Clinicians 1997, 47:5-27.
12. Lambert R., Hainaut P. The multidisciplinary management of gastrointestinal cancer. Epidemiology of oesophagogastric cancer. Best Practice and Research 2007, 21:921-945.
13. Brown L.M., Devesa S.S., Chow W.H. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. Journal of the National Cancer Institute 2008, 100:1184-1187.
14. Coupland V.H., Allum W., Blazeby J.M., et al. Incidence and survival of oesophageal and gastric cancer in England between 1998 and 2007, a population-based study. BMC Cancer 2012, 12:11.
15. Yousef F., Cardwell C., Cantwell M.M., Galway K., Johnston B.T., Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. American Journal of Epidemiology 2008, 168:237-249.
16. Hvid-Jensen F., Pedersen L., Drewes A.M., Sorensen H.T., Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. The New England Journal of Medicine 2011, 365:1375-1383.
17. Kubo A., Corley D.A. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiology, Biomarkers and Prevention 2006, 15:872-878.
18. Hampel H., Abraham N.S., El-Serag H.B. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Annals of Internal Medicine 2005, 143:199-211.
19. Whiteman D.C., Sadeghi S., Pandeya N., et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008, 57:173-180.
20. Engel L.S., Chow W.H., Vaughan T.L., et al. Population attributable risks of esophageal and gastric cancers. Journal of the National Cancer Institute 2003, 95:1404-1413.
21. Jankowski J.A., Wright N.A., Meltzer S.J., et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. The American Journal of Pathology 1999, 154:965-973.
22. Chandrasoma P.T., Der R., Ma Y., Peters J., Demeester T. Histologic classification of patients based on mapping biopsies of the gastroesophageal junction. The American Journal of Surgical Pathology 2003, 27:929-936.
23. Vogelstein B., Fearon E.R., Hamilton S.R., et al. Genetic alterations during colorectal-tumor development. The New England Journal of Medicine 1988, 319:525-532.
24. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus 2005, British Society of Gastoenterology (BSG).
25. Wang K.K., Sampliner R.E. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. The American Journal of Gastroenterology 2008, 103:788-797.
26. Agnese V., Cabibi D., Calcara D., et al. Aurora-A overexpression as an early marker of reflux-related columnar mucosa and Barrett's oesophagus. Annals of Oncology 2007, 18(Suppl. 6):vi110-vi115.
27. Cabibi D., Fiorentino E., Pantuso G., et al. Keratin 7 expression as an early marker of reflux-related columnar mucosa without intestinal metaplasia in the esophagus. Medical Science Monitor 2009, 15:CR203-CR210.
28. Cabibi D., Fiorentino E. Columnar-lined esophagus CK7 positive is an early marker of gastroesophageal reflux disease. The American Journal of Surgical Pathology 2011, 35(5):773. [author reply 773-4].
29. Kelty C.J., Gough M.D., Van Wyk Q., Stephenson T.J., Ackroyd R. Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. Scandinavian Journal of Gastroenterology 2007, 42:1271-1274.
30. Takubo K., Aida J., Naomoto Y., et al. Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Human Pathology 2009, 40:65-74.
31. Riddell R.H., Odze R.D. Definition of Barrett's esophagus: time for a rethink-is intestinal metaplasia dead?. The American Journal of Gastroenterology 2009, 104:2588-2594.
32. Dent J. Barrett's esophagus: a historical perspective, an update on core practicalities and predictions on future evolutions of management. Journal of Gastroenterology and Hepatology 2011, 26(Suppl. 1):11-30.
33. Spechler S.J. Dysplasia in Barrett's esophagus: limitations of current management strategies. The American Journal of Gastroenterology 2005, 100:927-935.
34. Abela J.E., Going J.J., Mackenzie J.F., McKernan M., O'Mahoney S., Stuart R.C. Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy. The American Journal of Gastroenterology 2008, 103:850-855.
35. Skacel M., Petras R.E., Gramlich T.L., Sigel J.E., Richter J.E., Goldblum J.R. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. The American Journal of Gastroenterology 2000, 95:3383-3387.
36. Dulai G.S. Surveying the case for surveillance. Gastroenterology 2002, 122:820-823.
37. Spechler S.J., Sharma P., Souza R.F., Inadomi J.M., Shaheen N.J. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011, 140:e18-e52. quiz e13.
38. Sato F., Jin Z., Schulmann K., et al. Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PloS ONE 2008, 3:e1890.
39. Macdonald C.E., Wicks A.C., Playford R.J. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. British Medical Journal 2000, 321:1252-1255. [Clinical Research Ed.].
40. Conio M., Blanchi S., Lapertosa G., et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. The American Journal of Gastroenterology 2003, 98:1931-1939.
41. Thomas T., de Caestecker J.S. Surveillance in Barrett's oesophagus. European Journal of Gastroenterology and Hepatology 2006, 18:585-588.
42. Eloubeidi M.A., Mason A.C., Desmond R.A., El-Serag H.B. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope?. The American Journal of Gastroenterology 2003, 98:1627-1633.
43. Fountoulakis A., Zafirellis K.D., Dolan K., Dexter S.P., Martin I.G., Sue-Ling H.M. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer. The British Journal of Surgery 2004, 91:997-1003.
44. Corley D.A., Levin T.R., Habel L.A., Weiss N.S., Buffler P.A. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002, 122:633-640.
45. Lekakos L., Karidis N.P., Dimitroulis D., Tsigris C., Kouraklis G., Nikiteas N. Barrett's esophagus with high-grade dysplasia: focus on current treatment options. World Journal of Gastroenterology 2011, 17:4174-4183.
46. Preston S.L., Jankowski J.A. Drinking from the fountain of promise: biomarkers in the surveillance of Barrett's oesophagus-the glass is half full!. Gut 2006, 55:1377-1379.
47. Dulai G.S., Guha S., Kahn K.L., Gornbein J., Weinstein W.M. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002, 122:26-33.
48. Reid B.J., Levine D.S., Longton G., Blount P.L., Rabinovitch P.S. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. The American Journal of Gastroenterology 2000, 95:1669-1676.
49. Galipeau P.C., Cowan D.S., Sanchez C.A., et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:7081-7084.
50. Reid B.J., Prevo L.J., Galipeau P.C., et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. The American Journal of Gastroenterology 2001, 96:2839-2848.
51. Galipeau P.C., Li X., Blount P.L., et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Medicine 2007, 4:e67.
52. Paulson T.G., Galipeau P.C., Reid B.J. Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. Genome Research 1999, 9:482-491.
53. Murray L., Sedo A., Scott M., et al. TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut 2006, 55:1390-1397.
54. Weston A.P., Banerjee S.K., Sharma P., Tran T.M., Richards R., Cherian R. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression. The American Journal of Gastroenterology 2001, 96:1355-1362.
55. Trudgill N.J., Suvarna S.K., Royds J.A., Riley S.A. Cell cycle regulation in patients with intestinal metaplasia at the gastro-oesophageal junction. Molecular Pathology 2003, 56:313-317.
56. Bani-Hani K., Martin I.G., Hardie L.J., et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. Journal of the National Cancer Institute 2000, 92:1316-1321.
57. Lao-Sirieix P., Lovat L., Fitzgerald R.C. Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance. Clinical Cancer Research 2007, 13:659-665.
58. Eads C.A., Lord R.V., Kurumboor S.K., et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Research 2000, 60:5021-5026.
59. Wang J.S., Guo M., Montgomery E.A., et al. DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. The American Journal of Gastroenterology 2009, 104:2153-2160.
60. Schulmann K., Sterian A., Berki A., et al. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 2005, 24:4138-4148.
61. Jin Z., Cheng Y., Gu W., et al. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Research 2009, 69:4112-4115.
62. Eads C.A., Lord R.V., Wickramasinghe K., et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Research 2001, 61:3410-3418.
63. Clark S.J., Harrison J., Paul C.L., Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Research 1994, 22:2990-2997.
64. Mutoh H., Satoh K., Kita H., et al. Cdx2 specifies the differentiation of morphological as well as functional absorptive enterocytes of the small intestine. The International Journal of Developmental Biology 2005, 49:867-871.
65. Silberg D.G., Furth E.E., Taylor J.K., Schuck T., Chiou T., Traber P.G. CDX1 protein expression in normal, metaplastic, and neoplastic human alimentary tract epithelium. Gastroenterology 1997, 113:478-486.
66. Guo R.J., Suh E.R., Lynch J.P. The role of Cdx proteins in intestinal development and cancer. Cancer Biology and Therapy 2004, 3:593-601.
67. Colleypriest B.J., Palmer R.M., Ward S.G., Tosh D. Cdx genes, inflammation and the pathogenesis of Barrett's metaplasia. Trends in Molecular Medicine 2009, 15:313-322.
68. Stairs D.B., Kong J., Lynch J.P. Cdx genes, inflammation, and the pathogenesis of intestinal metaplasia. Progress in Molecular Biology and Translational Science 2010, 96:231-270.
69. Garzon R., Calin G.A., Croce C.M. MicroRNAs in cancer. Annual Review of Medicine 2009, 60:167-179.
70. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
71. Carleton M., Cleary M.A., Linsley P.S. MicroRNAs and cell cycle regulation. Cell Cycle (Georgetown, TX) 2007, 6:2127-2132.
72. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nature Reviews 2009, 10:704-714.
73. Lowery A.J., Miller N., McNeill R.E., Kerin M.J. MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clinical Cancer Research 2008, 14:360-365.
74. Feber A., Xi L., Luketich J.D., et al. MicroRNA expression profiles of esophageal cancer. The Journal of Thoracic and Cardiovascular Surgery 2008, 135:255-260. [discussion 60].
75. Watson D.I., Michael W.B., Mayne M.Z.G.C.D.J.H. MicroRNA expression profiles in Barrett's oesophagus. ANZ Journal of Surgery 2007, 77:A45.
76. Yang H., Gu J., Wang K.K., et al. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clinical Cancer Research 2009, 15:5744-5752.
77. Krichevsky A.M., Gabriely G. miR-21: a small multi-faceted RNA. Journal of Cellular and Molecular Medicine 2009, 13:39-53.
78. Smith C.M., Watson D.I., Michael M.Z., Hussey D.J. MicroRNAs, development of Barrett's esophagus, and progression to esophageal adenocarcinoma. World Journal of Gastroenterology 2010, 16:531-537.
79. Hino K., Tsuchiya K., Fukao T., et al. Inducible expression of microRNA-194 is regulated by HNF-1alpha during intestinal epithelial cell differentiation. RNA (New York, NY) 2008, 14:1433-1442.
80. Mees S.T., Mardin W.A., Wendel C., et al. EP300-a miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas. International Journal of Cancer 2010, 126:114-124.
81. Braun C.J., Zhang X., Savelyeva I., et al. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Research 2008, 68:10094-10104.
82. Takagi T., Iio A., Nakagawa Y., Naoe T., Tanigawa N., Akao Y. Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology 2009, 77:12-21.
83. Liu X., Sempere L.F., Galimberti F., et al. Uncovering growth-suppressive MicroRNAs in lung cancer. Clinical Cancer Research 2009, 15:1177-1183.
84. Chen X., Guo X., Zhang H., et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009, 28:1385-1392.
85. Akao Y., Nakagawa Y., Iio A., Naoe T. Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells. Leukemia Research 2009, 33:1530-1538.
86. Spizzo R., Nicoloso M.S., Lupini L., et al. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death and Differentiation 2010, 17:246-254.
87. Suzuki H.I., Yamagata K., Sugimoto K., Iwamoto T., Kato S., Miyazono K. Modulation of microRNA processing by p53. Nature 2009, 460:529-533.
88. Georges S.A., Biery M.C., Kim S.Y., et al. Coordinated regulation of cell cycle transcripts by p53-inducible microRNAs, miR-192 and miR-215. Cancer Research 2008, 68:10105-10112.
89. Leidner R.S., Ravi L., Leahy P., et al. The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. Genes, Chromosomes and Cancer 2012, 51:473-479.
90. Smith C.M., Watson D.I., Leong M.P., et al. miR-200 family expression is downregulated upon neoplastic progression of Barrett's esophagus. World Journal of Gastroenterology 2011, 17:1036-1044.
91. Kwak P.B., Iwasaki S., Tomari Y. The microRNA pathway and cancer. Cancer Science 2010, 101:2309-2315.